Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy

Phase 2CompletedNCT02027818

Jules Bordet Institute20 enrolled

Overview

We will observe if ICG fluorescence correlates with margins of breast tumours after iv injection of the contrast agent

In the operating room: ICG 0.25 mg/kg will be given as an iv injection at least 20 minutes before the beginning of the operation. The surgeon will remove the tumour (and the axillary lymph nodes) as usual. Optionally, peroperative "in vivo" imaging of the dissection of the tumour using the PDE camera will be performed. In the Laboratory of Pathology: The "fresh" tumorectomy piece will be processed as usual, and the thick sections for the evaluation of the margins as well as the tissues samples from each margins will be imaged using the PDE in comparison with the fluorescence in the mid part of the tumour and the fluorescent areas will be so delimited (and later analyzed in comparison with standards of known fluorescence intensity). After fixation, the tumoral tissues will be thereafter processed "as usual". If fluorescent foci are identified at the level of the axillary piece (in case of CALND), they will be dissected and processed as other lymph nodes. Additionally, metastatic lymph nodes -if present- will also be controlled for their microscopic fluorescence or not. Using the near-infrared fluorescence microscope, the slides corresponding to the macroscopically fluorescent structures will be analyzed.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

Indocyanine GreenDRUG

Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with histopathological diagnosis of mammary cancer who are candidate for tumorectomy, either with SLN selective lymphadenectomy, or with complete axillary node dissection, * Informed consent form signed. Exclusion Criteria: * Diagnosis of mammary cancer established by "gross" biopsy, * Age less than18 years old. * Inability to give informed consent. * History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish. * Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland. * Documented coronary disease. * Advanced renal impairment (creatinine \> 1,5mg/dl). * During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin). * Pregnancy, breastfeeding

Locations (1)

Jules Bordet Institute

Brussels, Belgium

Outcomes

Primary Outcomes

- Evaluation of the ability of NIR imaging to show (fluorescent) the tumoral volumes, the tumoral tissues to be analyzed by the pathologist, especially at the level of the operative margins

Time frame: 17 months

Secondary Outcomes

- Analysis of the correlation between (levels of) ICG fluorescence and tumour margins as defined at the microscopic level by the pathologist

Time frame: 17 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.